Cargando...
Proteasome Inhibitors: Structure and Function
Since 2003, with the FDA approval of bortezomib, proteasome inhibitors have changed the management of hematologic malignancies and dramatically improved outcomes for patients with multiple myeloma and mantle cell lymphoma. Since that time, two additional proteasome inhibitors, carfilzomib and ixazom...
Guardado en:
| Publicado en: | Semin Oncol |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2018
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6020165/ https://ncbi.nlm.nih.gov/pubmed/29935898 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1053/j.seminoncol.2018.01.004 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|